Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 742 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glaucoma Clear all
Completed Phase 3 Interventional

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

NCT00061542
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
BETOPTIC S (betaxolol HCl), Timolol Gel-forming Solution (TGFS)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Week to 5 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Jul 22, 2026, 10:55 AM EDT
Completed No phase listed Observational Results available

Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops

NCT02138461
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
MDbackline, LLC
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Jul 22, 2026, 10:55 AM EDT
Not yet recruiting Not applicable Interventional

Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries

NCT07418853
View directory record Official record
Conditions
Open Angle Glaucoma (OAG), Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma
Interventions
Goniotomy
Procedure
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 10:55 AM EDT
Suspended Phase 1Phase 2 Interventional

Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT04761705
View directory record Official record
Conditions
Ocular Hypertension, Open Angle Glaucoma
Interventions
JV-GL1, Latanoprost 0.005% Ophthalmic Solution
Drug
Lead sponsor
JeniVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glaucoma Screening

NCT06186388
View directory record Official record
Conditions
Glaucoma
Interventions
TEMPO iMOvifa
Diagnostic Test
Lead sponsor
Cape Fear Eye Institute
Other
Eligibility
40 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2024 · Synced Jul 22, 2026, 10:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring

NCT06689696
View directory record Official record
Conditions
Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Interventions
miLens system
Device
Lead sponsor
Smartlens, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fullerton, California • Petaluma, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 10:55 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)

NCT02785042
View directory record Official record
Conditions
Glaucoma
Interventions
Heidelberg Spectralis OCT
Device
Lead sponsor
Heidelberg Engineering GmbH
Industry
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
8
States / cities
La Jolla, California • Santa Monica, California • Santa Rosa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 22, 2026, 10:55 AM EDT
Not yet recruiting No phase listed Observational

Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

NCT06023927
View directory record Official record
Conditions
Normal Tension Glaucoma, Obstructive Sleep Apnea
Interventions
Clinical observation, diagnostic testing
Other
Lead sponsor
Northwell Health
Other
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 22, 2026, 10:55 AM EDT
Recruiting Phase 3 Interventional

A Comparative, Randomized, Investigator-blind, Active-controlled, Parallel-group, Multicenter, Clinical Endpoint Study

NCT07661329
View directory record Official record
Conditions
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OH)
Interventions
Bimatoprost ophthalmic solution 0.01% YSBP, bimatoprost ophthalmic solution 0.01% (Lumigan®)
Drug
Lead sponsor
YS Life Science Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Beverly Hills, California • Inglewood, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

NCT01426113
View directory record Official record
Conditions
Glaucoma
Interventions
bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT02179008
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Chandler, Arizona • Artesia, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

NCT00652496
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NCT04452279
View directory record Official record
Conditions
Ocular Surface Disease, Glaucoma, Open-Angle
Interventions
iStent or iStent inject implantation with concomitant cataract surgery
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Jul 22, 2026, 10:55 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diagnostic Innovations in Glaucoma Study

NCT00221897
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Myopia
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

SENSIMED Triggerfish Safety and Tolerability

NCT01319617
View directory record Official record
Conditions
Glaucoma
Interventions
SENSIMED Triggerfish
Device
Lead sponsor
Sensimed AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2013 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optos P200TE Agreement and Precision Study

NCT03868462
View directory record Official record
Conditions
Retinal Disease, Glaucoma
Interventions
Optos P200TE, Predicate Device
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 22, 2026, 10:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Village-Integrated Eye Worker Trial II

NCT03752840
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions
Visual acuity (presenting and pinhole), Optical coherence tomography (OCT), Intraocular pressure, Active linkage to care, Fundus Photography
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older
Enrollment
60,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 22, 2026, 10:55 AM EDT
Completed Phase 4 Interventional

Lumigan Versus Cosopt

NCT00273455
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Louisville, Kentucky • Mt. Pleasant, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Jul 22, 2026, 10:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions

NCT01915680
View directory record Official record
Conditions
Glaucoma, Intraocular Pressure
Interventions
Not listed
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Jul 22, 2026, 10:55 AM EDT
Recruiting Not applicable Interventional

Electrical Stimulation for the Treatment of Optic Neuropathies

NCT05626426
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Optic Nerve Diseases
Interventions
Repetitive, Transorbital Alternating Current Stimulation (rtACS)
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Jul 22, 2026, 10:55 AM EDT
Withdrawn Phase 2 Interventional

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

NCT01997255
View directory record Official record
Conditions
Sturge Weber Syndrome
Interventions
Everolimus
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Jul 22, 2026, 10:55 AM EDT